Societies

Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial

Photo taken from Gonzalo Carreño Gómez-Tarragona/X

Jun 17, 2024, 01:15

Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial

Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared a post on X:

“Don’t miss the new findings of Proud-Continuation PV randomized trial showing the correlation between JAK2 mutation reduction with ropeginterferon alpha 2b and better event-free survival!

Molecular response is a meaningful goal of therapy in PV.”

Source: Jean-Jacques Kiladjian/X

cancer Cancer research EHA2024 JAK2 Jean-Jacques Kiladjian OncoDaily Oncology Paris Diderot University PV randomized trial ropeginterferon ropeginterferon alpha 2b

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage